Comparison of efficacy and local tolerability of estradiol metered-dose transdermal spray to estradiol patch in a network meta-analysis

References

• Gold EB. The timing of the age at which natural menopause occurs. Obstet Gynecol Clin N Am 2011;38:425–40
   PubMed Web of Science ®Google Scholar
• Bruce D, Rymer J. Symptoms of the menopause. Best Pract Res Clin Obstet Gynaecol 2009;23:25–32
   PubMed Web of Science ®Google Scholar
• Blake J. Menopause: evidence-based practice. Best Pract Res Clin Obstet Gynaecol 2006;20:799–839
   PubMed Web of Science ®Google Scholar
• DiBonaventura MD, Chandran A, Hsu MA, Bushmakin A. Burden of vasomotor symptoms in France, Germany, Italy, Spain, and the United Kingdom. Int J Women's Health 2013;5:261–9
   PubMedGoogle Scholar
• Goodman NF, Cobin RH, Ginzburg SB, Katz IA, Woode DE. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of menopause: executive summary of recommendations. Endocrine Pract 2011;17:949–54
   PubMedGoogle Scholar
• Panay N, Hamoda H, Arya R, Savvas M. The 2013 British Menopause Society & Women's Health Concern recommendations on hormone replacement therapy. Menopause Int 2013;19:59–68
   PubMedGoogle Scholar
• Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005;8(Suppl 1):3–63
   PubMed Web of Science ®Google Scholar
• Frenkel Y, Kopernik G, Lazer S, et al. Acceptability and skin reactions to transdermal estrogen replacement therapy in relation to climate. Maturitas 1994;20:31–6
   PubMed Web of Science ®Google Scholar
• Murphy M, Carmichael AJ. Transdermal drug delivery systems and skin sensitivity reactions. Incidence and management. Am J Clin Dermatol 2000;1:361–8
   PubMedGoogle Scholar
• Youngkin EQ. Estrogen replacement therapy and the estraderm transdermal system. Nurse Pract 1990;15:19–26
   PubMedGoogle Scholar
• Akhila V, Pratapkumar. A comparison of transdermal and oral HRT for menopausal symptom control. Int J Fertil Women's Med 2006;51:64–9
   PubMed Web of Science ®Google Scholar
• Berger RS, Della Cioppa G, Dillard CO. Skin tolerability and adhesion characteristics of a new matrix patch and a marketed reservoir patch for estradiol delivery. Menopause 1997;4:46–51
   Web of Science ®Google Scholar
• Rovati LC, Schmid K, Giacovelli G, et al. Efficacy on climacteric symptoms of a new estradiol transdermal patch with active matrix in comparison with a reference reservoir patch: Two long- term randomized multicenter parallel-group studies. Arzneim-Forsch Drug Res 1999;49:933–43
   PubMed Web of Science ®Google Scholar
• Rozenbaum H, Birkhauser M, De Nooyer C, et al. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). I. Tolerability, adhesion and efficacy. Maturitas 1996;25:161–73
   PubMed Web of Science ®Google Scholar
• Egras AM, Umland EM. The role of transdermal estrogen sprays and estradiol topical emulsion in the management of menopause-associated vasomotor symptoms. Int J Gen Med 2010;3:147–51
   PubMedGoogle Scholar
• Schumacher RJ, Gattermeir DJ, Peterson CA, Wisdom C, Day WW. The effects of skin-to-skin contact, application site washing, and sunscreen use on the pharmacokinetics of estradiol from a metered-dose transdermal spray. Menopause 2009;16:177–83
   PubMed Web of Science ®Google Scholar
• Buster JE, Koltun WD, Pascual MLG, Day WW, Peterson C. Low-dose estradiol spray to treat vasomotor symptoms: A randomized controlled trial. Obstet Gynecol 2008;111:1343–51
   PubMed Web of Science ®Google Scholar
• Caldwell DM. An overview of conducting systematic reviews with network meta-analysis. Syst Rev 2014;3:109
   PubMedGoogle Scholar
• Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices. 1. Value Health 2011;14:417–28
   PubMed Web of Science ®Google Scholar
• Haney EM, Huffman LH, Bougatsos C, Freeman M, Steiner RD, Nelson HD. Screening and treatment for lipid disorders in children and adolescents: systematic evidence review for the US Preventive Services Task Force. Pediatrics 2007;120:e189–214
   Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A 2009;172:137–59
   PubMed Web of Science ®Google Scholar
• VIVUS. A phase III multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of estradiol metered-dose transdermal spray (MDTS) in the treatment of vasomotor symptoms in postmenopausal women – clinical study report. Data on file, 2006
   Google Scholar
• De Aloysio D, Rovati LC, Giacovelli G, Setnikar I, Bottiglioni F. Efficacy on climacteric symptoms and safety of low dose estradiol transdermal matrix patches – A randomized, double-blind placebo-controlled study. Arzneim-Forsch Drug Res 2000;50:293–300
   PubMed Web of Science ®Google Scholar
• Haines C, Yu SL, Hiemeyer F, Schaefers M. Micro-dose transdermal estradiol for relief of hot flushes in postmenopausal Asian women: A randomized controlled trial. Climacteric 2009;12:419–26
   PubMed Web of Science ®Google Scholar
• Holst T, Salbach B. Efficacy of a new 7-day transdermal sequential estradiol/levonorgestrel patch in women. Maturitas 2002;41:231–42
   PubMed Web of Science ®Google Scholar
• Notelovitz M, Cassel D, Hille D, et al. Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2000;182:7–12
   PubMed Web of Science ®Google Scholar
• Pornel B, Genazzani AR, Costes D, Dain MP, Lelann L, Vandepol C. Efficacy and tolerability of Menorest® 50 compared with Estraderm® TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study. Maturitas 1995;22:207–18
   PubMed Web of Science ®Google Scholar
• Vrijer B, Snijders MPML, Troostwijk AL, et al. Efficacy and tolerability of a new estradiol delivering matrix patch (Estraderm MX®) in postmenopausal women. Maturitas 2000;34:47–55
   PubMed Web of Science ®Google Scholar
• MedDRA. Introductory Guide MedDRA Version 14.0 MedDRA; 2011 [10.11.2015]. Available from: http://www.who.int/medical_devices/innovation/MedDRAintroguide_version14_0_March2011.pdf
   Google Scholar
• Arrenbrecht S, Boermans AJM. Effects of transdermal estradiol delivered by a matrix patch on bone density in hysterectomized, postmenopausal women: A 2-year placebo-controlled trial. Osteoporosis Int 2002;13:176–83
   PubMed Web of Science ®Google Scholar
• Bacchi-Modena A, Bolis P, Campagnoli C, et al. Efficacy and tolerability of Estraderm MX®, a new estradiol matrix patch. Maturitas 1997;27:285–92
   PubMed Web of Science ®Google Scholar
• Bachmann GA, Schaefers M, Uddin A, Utian WH. Lowest effective transdermal 17β-estradiol dose for relief of hot flushes in postmenopausal women: A randomized controlled trial. Obstet Gynecol 2007;110:771–9
   PubMed Web of Science ®Google Scholar
• Cohen L, Coxwell WL, Melchione T, et al. Low-dose 17-beta estradiol matrix transdermal system in the treatment of moderate-to-severe hot flushes in postmenopausal women. Curr Ther Res Clin Exp 1999;60:534–47
   Web of Science ®Google Scholar
• Holst T, Salbach B. Efficacy and tolerability of a new 7-day transdermal estradiol patch versus placebo in hysterectomized women with postmenopausal complaints. Maturitas 2000;34:143–53
   PubMed Web of Science ®Google Scholar
• McKeever C, McIlwain H, Greenwald M, et al. An estradiol matrix transdermal system for the prevention of postmenopausal bone loss. Clin Ther 2000;22:845–57
   PubMed Web of Science ®Google Scholar
• Notelovitz M, John VA, Good WR. Effectiveness of Alora estradiol matrix transdermal delivery system in improving lumbar bone mineral density in healthy, postmenopausal women. Menopause 2002;9:343–53
   PubMed Web of Science ®Google Scholar
• Shulman LP, Yankov V, Uhl K. Safety and efficacy of a continuous once-a-week 17β-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: The results of two multicenter, double-blind, randomized, controlled trials. Menopause 2002;9:195–207
   PubMed Web of Science ®Google Scholar
• Utian WH, Burry KA, Archer DF, et al. Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. Am J Obstet Gynecol 1999;181:71–9
   PubMed Web of Science ®Google Scholar
• Adler G, Young D, Galant R, Quinn L, Witchger MS, Maki KC. A multicenter, open-label study to evaluate satisfaction and menopausal quality of life in women using transdermal estradiol/norethindrone acetate therapy for the management of menopausal signs and symptoms. Gynecol Obstet Invest 2005;59:212–19
   PubMed Web of Science ®Google Scholar
• Elia D, Tamborini A, Leocmach Y, Chadha-Boreham H. Efficacy and tolerability of a low-dose of Oesclim® (25 mcg daily) in the management of symptomatic menopausal women: A French open-label study. Curr Med Res Opin 2000;16:94–106
   PubMed Web of Science ®Google Scholar
• Hirvonen E, Cacciatore B, Wahlstrom T, Rita H, Wilén-Rosenqvist G. Effects of transdermal oestrogen therapy in postmenopausal women: A comparative study of an oestradiol gel and an oestradiol delivering patch. Br J Obstet Gynaecol 1997;104(Suppl 16):26–31
   PubMedGoogle Scholar
• Lopes P, Merkus HMWM, Nauman J, Bruschi F, Foidart JM, Calaf J. Randomized comparison of intranasal and transdermal estradiol. Obstet Gynecol 2000;96:906–12
   PubMed Web of Science ®Google Scholar
• Lopes P, Rozenberg S, De Graaf J, Fernandez-Villoria E, Marianowski L. Aerodiol® versus the transdermal route: perspectives for patient preference. Maturitas 2001;38(Suppl 1):S31–S9
   PubMedGoogle Scholar
• Lübbert H, Nauert C. Continuous versus cyclical transdermal estrogen replacement therapy in postmenopausal women: Influence on climacteric symptoms, body weight and bleeding pattern. Maturitas 1997;28:117–25
   PubMed Web of Science ®Google Scholar
• Mattsson LA, Bohnet HG, Gredmark T, Torhorst J, Hornig F, Hüls G. Continuous, combined hormone replacement: Randomized comparison of transdermal and oral preparations. Obstet Gynecol 1999;94:61–5
   PubMed Web of Science ®Google Scholar
• Mendoza N, Pisón JA, Fernández M, Sánchez MC, Malde J, Miranda JA. Prospective, randomised study with three HRT regimens in postmenopausal women with an intact uterus. Maturitas 2002;41:289–98
   PubMed Web of Science ®Google Scholar
• Parsey K, Ellman H, Rahman M. Randomised, controlled comparison of transdermal estradiol with oral conjugated estrogens for the relief of hot flushes. Clin Drug Invest 2000;20:207–14
   Web of Science ®Google Scholar
• Raynaud JP, Lévrier M, Calaf J, Laur C, Pélissier C. Comparison of the efficacy and tolerability of a new once-a-week matricial estradiol transdermal system (Estrapatch® 40 and Estrapatch® 60) with a twice week system. J Steroid Biochem Mol Biol 2005;93:309–18
   PubMed Web of Science ®Google Scholar
• Sturdee DW, van de Weijer P, von Holst T. Endometrial safety of a transdermal sequential estradiol-levonorgestrel combination. Climacteric 2002;5:170–7
   PubMed Web of Science ®Google Scholar
• Alexandersen P, Riis BJ, Christiansen C. Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: A randomized study. J Clin Endocrinol Metab 1999;84:3013–20
   PubMed Web of Science ®Google Scholar
• Baracat E, Yamada S, Haidar M, et al. Evaluation of skin tolerability in patients on a 7-day regimen of a new matrix transdermal estradiol delivery system: An open-label study. Curr Ther Res Clin Exp 1997;58:417–27
   Web of Science ®Google Scholar
• Jarupanich T, Lamlertkittikul S, Chandeying V. Efficacy, safety and acceptability of a seven-day, transdermal estradiol patch for estrogen replacement therapy. J Med Assoc Thailand 2003;86:836–45
   PubMedGoogle Scholar
• Palacios P, Schmidt G, Sergejew T, Quebe-Fehling E, Lockhart L, Krinsky L. Comparative study to evaluate skin irritation and adhesion of Estradot® and Climara® in healthy postmenopausal women. Climacteric 2002;5:383–9
   PubMed Web of Science ®Google Scholar
• Samsioe G, Boschitsch E, Concin H, et al. Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: A randomized open-label study. Climacteric 2006;9:368–79
   PubMed Web of Science ®Google Scholar
• Samsioe G, Dvorak V, Genazzani AR, et al. One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women. Maturitas 2007;57:171–81
   PubMed Web of Science ®Google Scholar
• Toole J, Silagy S, Maric A, Fath B, et al. Evaluation of irritation and sensitisation of two 50 μg/day oestrogen patches. Maturitas 2002;43:257–63
   PubMed Web of Science ®Google Scholar
• Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: A randomized clinical trial. Obstet Gynecol 2004;104:443–51
   PubMed Web of Science ®Google Scholar
• Post MS, Thomassen MCLGD, Van der Mooren MJ, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: A randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003;23:1116–21
   PubMed Web of Science ®Google Scholar
• Rubinacci A, Peruzzi E, Modena AB, et al. Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women. Menopause 2003;10:241–9
   PubMed Web of Science ®Google Scholar
• Lake Y, Pinnock S. Improved patient acceptability with a transdermal drug-in-adhesive oestradiol patch. Aust N Z J Obstet Gynaecol 2000;40:313–16
   PubMed Web of Science ®Google Scholar
• Good WR, John VA, Ramirez M, Higgins JE. Double-masked, multicenter study of an estradiol matrix transdermal delivery system (AloraTM) versus placebo in postmenopausal women experiencing menopausal symptoms. Clin Ther 1996;18: 1093–105
   PubMed Web of Science ®Google Scholar
• Oosterbaan HP, van Buuren AHJAM, Schram JHN, et al. The effects of continuous combined transdermal oestrogen-progestogen treatment on bleeding patterns and the endometrium in postmenopausal women. Maturitas 1995;21:211–19
   PubMed Web of Science ®Google Scholar